期刊文献+

重组人胰高血糖素样肽-1的表达及生物学活性 被引量:7

Expression and Bioactivites of Recombinant Human Glucagon-like Peptide-1
下载PDF
导出
摘要 将人工合成的人胰高血糖素样肽-1(human glucagon—like peptide-1,hGLP-1)基因插入质粒栽体pET-32a(+)中,构建成rhGLP-1与硫氧还蛋白(thioredox)及六聚组氨酸(hexahistidine)的融合表达栽体pET32-GLP-1,转化大肠杆菌BL21(DE3)获得表达菌株,经LPTG诱导发酵的菌体超声破碎后,裂解液用Ni离子亲和层析纯化得到融合蛋白,经肠激酶裂解,再次Ni离子亲和层析,得到rhGLP-1样品。经SDS—PAGE和等电聚焦检测,样品纯度大于90%,等电点介于pH5.2-pH5.85之间。质谱测定rhGLP-1分子量为3355.0kDa,肽图分析得到2097.7kDa和1005.5kDa两个胰蛋白酶酶解片断,均与理论分析结果一致。动物实验表明重组蛋白具有明显的降血糖活性和促胰岛素分泌作用。 The synthesized full-length hGLP-1 gene was cloned into pET-32a( + ) to get the recombinant plasmid pET32-GLP-1, which could express a fusion protein containing thioredox, hexahistidine, and rhGLP-1 consecutively. The recombinant plasmid containing hGLP-1 was transformed into E. coli BL21 (DE3) and expressed by IPTG induction. The fusion protein was purified from lysates with Ni ~ IDA His· Bind affinity chromatography, rhGLP-1 with the purity of 90% was achieved after enterokinase digestion, Ni · IDA His · Bind affinity chromatography again, then was concentrated by ultrafiltration. The purified rhGLP-1 showed a single band on IEF gel with an isoelectric point between pHS. 2 and pI-IS. 85. ESI mass spectrometry showed that the molecular weight was 3355.0kDa as expected, rhGLP-1 was digested with trypsin followed by mass analysis and the peptide mapping produced two expected fragments with the molecular weights of 2097.7kDa and 1005.5kDa, respectively. The purified rhGLP-1 also showed obvious biological activity for both lowering plasma glucose and stimulating insulin secretion in mice.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2006年第1期50-55,共6页 China Biotechnology
关键词 胰高血糖素样肽-1 表达 生物学活性 Glucagon-like peptide-1 ( GLP-1 ) Expression Bioactivity
  • 相关文献

参考文献12

  • 1Cecile T, Danielle B, Matthieu L, et al. Glucagon-like peptide-1 and exendin-4 stimulate β-call neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult ages. Diabetes, 2002,51:1443 - 1452. 被引量:1
  • 2Takei I, Kasatani T. Future therapy of diabetes mellitus.Biomedicine & Pharmacotherapy, 2004,58: 578 -581. 被引量:1
  • 3Jeandidier N, Boivin S. Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment. Advanced Drug Delivery Reviews, 1999,35 : 179 - 198. 被引量:1
  • 4Holst J J. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends in Endocrinology and Metabolism, 1999, 10(6) : 229 -235. 被引量:1
  • 5赖玉平,彭沂非,郁正艳,黄静,吴自荣.DCD-1L在毕赤酵母中的克隆和表达[J].中国生物工程杂志,2004,24(2):61-65. 被引量:14
  • 6高锦,王艳丽,魏群.HPLC和MALDI-TOF-MS法分析重组人钙调磷酸酶B亚基的纯度和肽图谱[J].北京师范大学学报(自然科学版),2004,40(1):114-119. 被引量:3
  • 7Edelstein S J. Protein Methods. Oxford: Wiley-Liss Inc, 1991.162 - 171. 被引量:1
  • 8O'Harte F P M, Mooney M H, Lawlor A, et al. N-terminally modified glucagon-like peptide-1 (7 - 36 ) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochimica et Biophysica Acta, 2000, 1474:13 -22. 被引量:1
  • 9Siegel E G, Gallwitz B, Scharf G, et al. Biologicalactivity of GLP 1 analogues with N-terminal modifications. Regulatory Peptides, 1999, 79:93 - 102. 被引量:1
  • 10Holst J J, Deacon C F. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase Ⅳ in the treatment of type 2 diabetes mellitus. Current Opinion in Pharmacology, 2004, 4(6) : 589- 596. 被引量:1

二级参考文献8

  • 1[1]Liu J, Jr Farmer J D, Lane W S, et al. Calcineurin is a common target of cyclophlin-chclosporin A and FKBP-FK506 complexes[J]. Cell, 1991, 66:807 被引量:1
  • 2[2]Geiffith J P, Kim J L, Kim E E, et al. FKBP12 and CyP are small, ubiquitous cytosolic proteins that function enzymatically as cis-trans peptidyl prolyl isomerases[J]. Cell, 1995, 82:570 被引量:1
  • 3[3]Alice Haddy, Selene K, Swanson-H, et al. Inhibition of calcineurin by cyclosporin A-cyclosphilin requires calcineurin B[J]. FEBS, 1992, 317(1):37 被引量:1
  • 4[4]Timmerman L A, Clipstone N A. Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression[J]. Nature, 1996, 383:837 被引量:1
  • 5[5]Wang H G, Pathan N, Ethell I M, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BHD[J]. Science, 1999, 284:339 被引量:1
  • 6[6]Srivastava R K, Sasaki C Y, Hardwick J M, et al. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes(NFAT)-induced fas ligand transcription[J]. J Exp Med, 1999, 190:253 被引量:1
  • 7[7]Wei Qun, Lian Mulan, Jing Fengzhi, et al. Studies of calcineurin B subunit from genetic engineering for use in medicine[J]. Drug Development Research, 2002, 51:1 被引量:1
  • 8胡福泉.肽抗生素研究进展及其应用前景[J].微生物学杂志,2003,23(2):59-60. 被引量:2

共引文献15

同被引文献82

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部